Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 235,882 shares of the company’s stock after buying an additional 5,454 shares during the period. JPMorgan Chase & Co. owned about 0.41% of Harmony Biosciences worth $8,117,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Harmony Biosciences by 36.4% in the fourth quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock valued at $162,883,000 after buying an additional 1,262,362 shares during the last quarter. Pacer Advisors Inc. boosted its stake in Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after purchasing an additional 351,582 shares during the period. American Century Companies Inc. grew its position in Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company’s stock worth $37,941,000 after purchasing an additional 246,140 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Harmony Biosciences by 27.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 472,028 shares of the company’s stock valued at $16,242,000 after purchasing an additional 100,586 shares during the period. Finally, Capital Management Corp VA raised its holdings in shares of Harmony Biosciences by 43.5% during the fourth quarter. Capital Management Corp VA now owns 340,960 shares of the company’s stock valued at $11,732,000 after buying an additional 103,308 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on HRMY shares. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Finally, Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday, March 18th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $53.33.

Insider Activity

In other news, insider Jeffrey Dierks sold 1,123 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.00, for a total transaction of $44,920.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,945 shares of company stock worth $2,442,815. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $28.75 on Wednesday. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average price is $33.49 and its 200 day moving average price is $34.66. Harmony Biosciences Holdings, Inc. has a 52-week low of $26.47 and a 52-week high of $41.61. The firm has a market cap of $1.65 billion, a P/E ratio of 13.63, a PEG ratio of 0.47 and a beta of 0.80.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.11. The business had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. As a group, sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.